A haematological study of patients receiving long-term treatment with trimethoprim and sulphonamide.
The haematological effects of long-term treatment for three months with a combination of trimethoprim and sulphamethoxazole were studied in 10 cases of chronic bronchitis. Trimethoprim selectively inhibits dihydrofolate reductase in bacteria but not in man. Only minor effects on folate metabolism were observed in nine cases, causing no clinical concern. Some degree of thrombocytopenia occurred in the tenth case which improved when folinic acid was given.
D000368:Aged; D001772:Blood Cell Count; D001792:Blood Platelets; D001991:Bronchitis / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004906:Erythrocyte Count; D005260:Female; D005492:Folic Acid / Q000097:blood*; D005493:Folic Acid Antagonists / Q000009:adverse effects*; D006452:Hemoglobinometry; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009504:Neutrophils; D011743:Pyrimidines / Q000009:adverse effects*; D013420:Sulfamethoxazole / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
D005493:Folic Acid Antagonists; D011743:Pyrimidines; D005492:Folic Acid; D013420:Sulfamethoxazole